Indefinite Delivery Contract 75D30126D20724
Award Date 12/31/25
Last Date to Order 2/28/27
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed Similar IDVs
- The Centers for Disease Control and Prevention (CDC), operating through its Pittsburgh office, awarded a Multiple Award Indefinite Delivery Contract to GlaxoSmithKline, LLC for the Vaccines for Children (VFC) program with a ceiling value of $1.49 billion and a performance period from April 1, 2025, through March 31, 2026. This civilian contract, which received no set-aside designation, procures standard commercial pediatric vaccines to support immunization efforts for eligible populations,...
- The Centers for Disease Control and Prevention (CDC) awarded a single award Indefinite Delivery Contract to Glaxosmithkline, LLC, a pharmaceutical company, to procure pediatric influenza vaccines for the 2022-2023 season. The contract has a potential value of $168,590,000 and a period of performance from the date of award through February 28, 2023. The original solicitation sought between 100 doses and 50 million doses of pediatric influenza vaccine to be delivered to CDC distribution centers in...
- The Centers for Disease Control and Prevention awarded multiple indefinite delivery contracts under the Vaccines for Children 2021 program to support pediatric immunization efforts. The contracts hold a potential value of $1.039 billion and were awarded to Glaxosmithkline, LLC for the period of April 1, 2021 through March 31, 2022. The contracts will provide 20 standard pediatric vaccines to the CDC's Immunization Awardees for distribution through the Vaccines for Children program and Section...
- This indefinite delivery contract, awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC, provides for the purchase of 20 different pediatric vaccines for the CDC's Vaccines for Children program. The contract has a $986,824,450 ceiling value and a period of performance from April 1, 2020 through March 31, 2021. Glaxosmithkline, as the prime contractor, will supply vaccines such as DTaP, Hep A and B, Hib, HPV, MMR, pneumococcal, rotavirus, and varicella in...
- The federal contract IDV award to Glaxosmithkline, LLC is for the supply of pediatric influenza vaccines to the Centers for Disease Control and Prevention (CDC) for distribution to immunization programs under the Section 317(j) Public Health Service Act and Vaccines for Children program. The single-award contract has a ceiling value of $161,025,000 and a period of performance from December 31, 2020 to February 28, 2022. The contract was issued in response to a CDC solicitation for a minimum...
- This indefinite delivery contract was awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC as the prime contractor. The contract, valued at up to $1.25 billion, is part of the Vaccines for Children (VFC) 2015 program and provides for the delivery of various vaccines and pharmaceutical products to support federal immunization and disease prevention initiatives. Key products and services included under this multiple award IDV contract include seasonal influenza...
- This Indefinite Delivery Contract award provides for the procurement of pediatric influenza vaccines under the 2025-6 program, funded by the Centers for Disease Control and Prevention (CDC) Pittsburgh office. The contract was awarded on December 31, 2024, to Glaxosmithkline, LLC, a pharmaceutical company headquartered in Durham, North Carolina, with a ceiling value of $182.592 million and an ultimate completion date of February 28, 2026. The award represents a multiple-award contract with no...
- This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC, a foreign-owned, for-profit pharmaceutical company, to provide a wide range of pediatric vaccines over a period of performance from April 1, 2024 to March 31, 2025. The contract has a ceiling value of $1,334,738,300 and is part of the CDC's National Center for Immunization and Respiratory Diseases (NCIRD) effort to support pediatric immunization programs under...
- This indefinite delivery contract was awarded by the Centers for Disease Control and Prevention (CDC) Office of Acquisition Services, a civilian federal agency, to GlaxoSmithKline Holdings (Americas) Inc. The single-award contract has a ceiling value of $11,968,367.50 and a period of performance from March 15, 2010 to February 28, 2011. The contract aims to procure influenza vaccine services for the CDC's Vaccine for Children (VFC) program in 2010. The VFC program provides vaccines at no cost to...
- This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC, a pharmaceutical company, to provide a range of pediatric vaccines for the Vaccines for Children (VFC) program. The $1.26 billion, multiple-award IDC has a period of performance from April 1, 2023 through March 31, 2024. The contract aims to procure a minimum of 100 doses up to a maximum ranging from 100,000 to 13 million doses of 21 different pediatric vaccines,...